SEC Filing Summary: Aadi Bioscience, Inc. (AADI)
Business Context and Reporting Period
This Form 8-K was filed on March 24, 2023, by Aadi Bioscience, Inc. (Note: The input metadata references "Whitehawk Therapeutics," but the filing text explicitly identifies the registrant as Aadi Bioscience, Inc.). The report covers two primary events: the announcement of financial results for the fiscal year ended December 31, 2022, and the appointment of a new director.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the fiscal year ended December 31, 2022. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release and are not detailed in the current document.
Material Changes and Corporate Governance
- Board Appointment: On March 24, 2023, the Board appointed Mohammad Hirmand, M.D., as a Class II director, effective March 27, 2023. This appointment fills the vacancy left by the resignation of Brendan Delaney.
- Compensation Arrangements: Dr. Hirmand will receive a base annual retainer of $40,000. Additional compensation is available for committee service (ranging from $4,500 to $20,000 annually depending on role). He will also receive an initial stock option grant with a grant date fair value of $325,000, vesting monthly over 36 months.
- Independence: The Board determined Dr. Hirmand meets the independence requirements under Nasdaq listing standards.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard legal disclaimers. The document notes that the information furnished in Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 28, 2023) for specific financial metrics (revenue, net loss, cash position) for the fiscal year ended December 31, 2022.
- Verify the impact of the new director's stock option grant ($325,000 fair value) on potential dilution.
- Confirm the status of the company's cash runway and operational milestones in the full press release, as the 8-K summary does not provide these details.
- Note the discrepancy between the metadata company name ("Whitehawk Therapeutics") and the filing registrant ("Aadi Bioscience, Inc.") to ensure the correct entity is being analyzed.